Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major

Carla Casu, Vania Lo Presti, Paraskevi Rea Oikonomidou, Luca Melchiori, Osheiza Abdulmalik, Pedro Ramos, and Stefano Rivella

Disclosures: S.R. is a consultant for Ionis Pharmaceuticals. In addition, S.R. is a co-inventor for the patents US8058061 B2 C12N 20111115 and US7541179 B2 C12N 20090602. The consulting work and intellectual property of S.R. did not affect in any way the design, conduct, or reporting of this research. L. M. is employee of Adaptimmune Therapeutics Ltd. P. R. is employee of Novartis Pharma AG. The remaining authors declare no competing financial interests.

Contributions: C.C. performed research, analyzed results and wrote the paper; V.L.P. and P.R.O. performed research and revised the paper; L.M. conceived the original study and revised the manuscript; A.O. and P.R. revised the manuscript; S.R. designed research, analyzed results and wrote the paper.